Endothelial Cell Markers and the Risk of Coronary Heart Disease

Abstract

on behalf of the PRIME Study Group Background-Tissue factor pathway inhibitor (TFPI), von Willebrand factor (vWF), and thrombomodulin (TM) are 3 major hemostatic regulatory molecules synthesized by endothelium. Data from epidemiological studies aiming to evaluate the relation between plasma levels of these molecules and the development of coronary heart disease (CHD) are sparse or contradictory. Methods and Results-We examined the association between these endothelial-cell markers and the incidence of fatal or nonfatal myocardial infarction (hard CHD) and stable or unstable angina (angina pectoris) in a prospective cohort (the PRIME Study) of nearly 10 000 healthy men recruited in France and Northern Ireland. We measured baseline plasma concentration of the free form of TFPI (f-TFPI), vWF, and the soluble form of TM (sTM) among 296 participants who subsequently developed CHD over the 5-year follow-up (158 with hard CHD and 142 with angina pectoris) and in 563 control subjects by use of a nested case-control design. Individuals with plasma vWF levels in the highest quartile showed a 3.04-fold increase in the risk of hard CHD compared with those in the lowest quartile (95% CI, 1.59 to 5.80). Individuals with f-TFPI levels below the 10th percentile had a 2.13-fold increased risk of hard CHD compared with those with levels above it (95% CI, 1.08 to 4.18). The risk for both molecules persisted after control for inflammatory parameters. Individuals with vWF levels in the highest quartile and f-TFPI levels below the 10th percentile presented a 6.9-fold increased risk of hard CHD compared with those with vWF levels in the lowest quartile and f-TFPI levels above the 10th percentile (95% CI, 1.3 to 37.8). Conclusions-vWF and f-TFPI plasma levels were independent risk factors for hard CHD events.

Endothelial cell markers in coronary artery disease

“…This parameter was not statistically increased in any of the groups. Data from the literature demonstrate increased, decreased and unchanged concentrations of sTM in patients with CAD [2,9,11]. The discrepancy between these results may be an effect of synergy between two opposing mechanisms: increased release of sTM from the endothelium caused by currently acting damaging factors and decreased TM expression from the whole endothelial surface in patients with coronary artery disease.…”

Associations of Thrombotic-Hemostatic Factors with Cardiovascular Disease~!2009-10-29~!2009-12-22~!2010-04-08~!

“…A large prospective study yielded encouraging results showing a moderately significant association between vW and CHD even after adjustment for baseline values of classical risk factors (OR in the top vs. the bottom third 1.82, 95% CI 1.37-2.41) [144]. Moreover, the PRIME study showed a 3.04-fold increase in the risk of MI and coronary death in patients with plasma vW levels in the highest vs. the lowest quartile (95% CI, 1.59 to 5.80) [145].…”

Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure

“…However, two prospective clinical studies indicate that low circulating levels of TFPI are associated with increased risk of vascular disease and thrombosis. In the PRIME study (31), low circulating levels of TFPI were associated with a two-fold increased risk of hard coronary heart disease events (fatal and nonfatal myocardial infarction). Furthermore, low levels of TFPI were associated with risk of deep venous thrombosis in the Leiden Thrombophilia Study (32).…”